Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
DOMH
DOMH | US
3.09
USD0.09
3.00%
DOMH | US
About DOMH
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
14/04/2026
Close
3.09
Open
2.98
High
3.17
Low
2.95
Dominari Holdings Inc. a biotechnology company focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer pancreatic cancer acute myeloid leukemia (AML) and acute lymphoblastic leukemia. It is developing DHA-dFdC a pancreatic drug candidate; and KPC34 a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses including influenza virus Ebolavirus and Marburg virus SARS-CoV MERS-CoV and SARS-CoV-2. It has license agreements with the University of Texas Silo Pharma Inc. and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York New York.
View LessDOMH | US
Risk
83.7
Sharpe
-0.07
Luna's Score
51/100
Recommendation
Hold
Luna says (DOMH | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
104.0%1 month
83.7%3 months
69.5%6 months
75.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.27
Debt to equity
0.08
Debt to assets
0.07
Ent. to EBITDA
1.70
Ent. to rev.
0.26
PEG
-
Other Fundamentals
EBITDA
-14.09M
MarketCap
19.39M
MarketCap(USD)
19.39M
Div. yield
-
Op. margin
-44.31
Erngs. growth
-
Rev. growth
8.60K
Ret. on equity
-42.29
Short ratio
0.32
Short perc.
0.11
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.59
Range1M
0.75
Range3M
1.66
Volumes: Market Activity
Rel. volume
0.74
Price X volume
321.06K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.70 | - | Expensive |
| Ent. to Revenue | 0.26 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.27 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 69.54 | - | Par |
| Debt to Equity | 0.08 | -1.23 | Expensive |
| Debt to Assets | 0.07 | 0.25 | Cheaper |
| Market Cap | 19.39M | - | Emerging |
